Table 3.

Cytoreductive surgery and hyperthermic perioperative chemotherapy for proactive management of local recurrence and peritoneal metastases for colorectal cancer

Credits	Debits
Long-term survival in 50% of patients	Many patients treated for a few to benefit
Selection factors have been well defined	The surgical technology is complex and requires an extended learning curve
An important addition to the MDT for management of colorectal malignancy	Referral by medical oncologist are often late with a large extent of disease
Morbidity (10%) and mortality (1%) at experienced centers is acceptable	So far a uniform HIPEC treatment has not emerged; perioperative chemotherapy needs to be optimized

HIPEC: Hyperthermic perioperative chemotherapy.